Preferably the case is written for a bigger player within the pharmaceutical industry, like Johnson & Johnson
In the last decades, the world has seen many drug shortages that impact the availability of drugs for many different treatments. The FDA and EMA has set up initiatives to combat these drug shortages by requesting earlier reports of potential drug shortages and having a tighter oversight on the supply chain of these companies.
Early 2020, the COVID-19 pandemic started and again, drug shortages became a world wide problem and the FDA and EMA saw in increase in reported potential drug shortages. The FDA and the EMA are trying to combat the problem by gaining more oversight in the supply chains and try to resolve the potential drug shortages before they actually occur. However, this does not solve the Root Cause of the problem. Additionally, companies experience a huge waste on potential drug shortages that need to be reported and investigated, while the issue can be many months away. To reduce this waste, what can the companies do to build a more resilient supply chain and reduce the amount of potential drug shortages from even occurring in the first place and reduce the required reporting to the respective health authorities.
See attached and: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/availability-medicines
Related Completed Projects
Explain the main features of the ethical theories of Ruth Benedict and James Rachels, Plato, Aristotle, Kant, and Mill.
Describe the ″Economics of Happiness″.
DISCUSS AN INTERNATIONAL BUSINESS, MARKETING, AND BRANDING INTEGRATED SERVICES MARKETING.
Discuss the Disorders of the Male Reproductive System.